Combining interleukin 6 and EBV DNA levels predicts survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving chemoimmunotherapy
This model predicted both PFS and OS in R/M NPC patients undergoing chemoimmunotherapy. This finding may help clinicians with an initial prognostic estimation but warrants further prospective investigation for the value of IL-6 and EBV DNA.
Authors
- Chen Chen (ORCID: https://orcid.org/0000-0002-8303-2862)
- Ya Liu (ORCID: https://orcid.org/0000-0002-7816-684X)
- Ping Feng (ORCID: https://orcid.org/0009-0005-8648-3318)
- Yujun Hu
- Songran Liu (ORCID: https://orcid.org/0000-0001-8770-7962)
- Zilu Huang
- Shuohan Zheng
- Yunfei Xia
- Yalan Tao
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Hengyang Academy of Agricultural Sciences (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1560897
- Citations
- 2
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.70